who's who

3 Houston innovators to know this week

This week's innovators to know in Houston includes Marcelo Cordini of December Labs, Courtney Sikes Longmore of Pure Palate, and Josh Ruben of Z3VR. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators representing a diverse set of industries — from virtual reality to software development — all making headlines in Houston this week.

Marcelo Cordini, co-founder of December Labs

Marcelo Cordini, co-founder of December Labs, joins the Houston Innovators Podcast to discuss the unique service his company provides an evolving tech workforce. Photo courtesy of December Labs

Marcelo Cordini realized that nowadays, software developers are like rockstars. They can make or break a startup or technology's success and finding the best development team can be hard to do. But hiring and cultivating software talent is a specialty most companies — big or small — has the time or expertise to handle. That's where December Labs comes in.

"We are always learning new technologies — that's our focus," Cordini says. "If you have a big company focused on real estate, your focus is on real estate — not technology. So, if you partner with a company like us, it will give you that value to have someone who knows how to hire developers and how to train them."

Cordini joined the Houston Innovators Podcast last week to discuss the unique service his company provides and the state of software employment is in these days. Read more and stream the episode.

Courtney Sikes Longmore, founder at Pure Palate

Women in the work place have been hit the hardest by the pandemic. Photo via Pexels

According to Labor Department statistics, 1.1 million people left the workforce in August and September, and of that 800,000 were women. This data wasn't surprising to Courtney Sikes Longmore, an entrepreneur and founder of Pure Palate — however it was a call to action. She teamed up with Sesh Coworking to host a panel (click here to stream) to discuss how COVID-19 has disproportionately affected women and co-wrote a guest article with Maggie Segrich on the subject too.

"A decline of women in the labor force, on teams, in leadership positions and in decision-making roles compromises not just our economy's recovery and productivity, but also the innovation and effectiveness in industry, competitiveness on a global scale, aspirations of future generations of women, and society as a whole," they write. Read more.

Josh Ruben, CEO of Z3VR

Houston-based Z3VR has been granted $500,000 to work or virtual reality applications in space. Photo courtesy of Z3VR

The Houston-based Translational Research Institute for Space Health is always trying to find and support innovations that will help current and future astronauts, and Josh Ruben's company, Z3VR, was a perfect fit to work on virtual reality applications in space. The company received a $500,000 grant from TRISH last month to continue exploring how the wide world of virtual reality can boost mental and physical health for astronauts on a mission to Mars.

"This TRISH funding means the world," he says. "Not only do we have these partnerships within NASA, which we expect will really help address these problems, but we are already taking the funds and putting them to work in the US health care system." Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted